Topics

A Monotherapy in Subjects With Advanced Solid Tumors

2020-01-14 10:02:54 | BioPortfolio

Summary

A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics Profiles, and Preliminary Efficacy of 3D185 Monotherapy in Subjects with Advanced Solid Tumors

Description

Subjects with advanced solid tumors who have no available standard therapy or who have failed standard therapies.

This is an open-label, global multicenter, dose-escalation phase 1 study of safety, tolerability, preliminary PK profile, and preliminary efficacy of 3D185 monotherapy in subjects with advanced solid tumors.

The starting dose in this dose-escalation study is 25 mg, and the preset 7 dose-escalation cohorts are 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg, respectively.

Study Design

Conditions

Solid Tumor, Adult

Intervention

Highly selective FGFR1-3 inhibitor

Location

Affiliated Hospital of Military academy of medical sciences
Beijing
China
100071

Status

Recruiting

Source

3D Medicines (Sichuan) Co., Ltd.

Results (where available)

View Results

Links

Published on BioPortfolio: 2020-01-14T10:02:54-0500

Clinical Trials [3735 Associated Clinical Trials listed on BioPortfolio]

K-BASKET, TAS-117, PI3K/AKT Gene Aberration

The phosphatidylinositol 3-kinase (PI3K)-v-akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) signaling pathway is one of the most frequently aberrantly r...

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Isunakinra - a potent Interleukin-1 receptor inhibitor - will be given to patients with solid tumors to determine safety and tolerability of three different doses. Isunakinra will then be ...

A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

HS-196 is near infrared red (NIR)-tethered HSP90 inhibitor for clinical imaging of selective tumor binding. HS-196 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP b...

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety. The study will also investigate prelimi...

HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies

HS-201 is Verteporfin-tethered HSP90 inhibitor for clinical imaging of selective tumor binding. HS-201 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domai...

PubMed Articles [22928 Associated PubMed Articles listed on BioPortfolio]

Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.

FGF2-FGFR1 autocrine pathway activation reduces the sensitivity of non-small cell lung cancer (NSCLC) cells to EGFR inhibitors like Gefitinib. Therefore, dual-specific drugs targeting EGFR and FGFR wi...

Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer.

MicroRNA (miRNA) and fibroblast growth factor receptor 1 (FGFR1) dysregulation are considered to play an important role in tumor proliferation, invasion, and metastasis. However, the regulatory mechan...

Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.

p300/CBP are ubiquitously expressed pleiotropic lysine acetyl transferases and play a key role as transcriptional co-activators that are essential for a multitude of cellular processes. Despite great ...

Structure-based design of a potent and selective covalent inhibitor for SRC kinase that targets a p-Loop cysteine.

SRC is a major regulator of many signaling pathways and contributes to cancer development. However, development of a selective SRC inhibitor has been challenging, and FDA-approved SRC inhibitors, dasa...

Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.

Recently, selective inhibition of BET BD2 is emerging as a promising strategy for drug discovery. Despite significant progress in this area, systematic studies of selective BET BD2 inhibitors are stil...

Medical and Biotech [MESH] Definitions

A reagent that is highly selective for the modification of arginyl residues. It is used to selectively inhibit various enzymes and acts as an energy transfer inhibitor in photophosphorylation.

A solid, unencapsulated tumor of the KIDNEY composed of spindle mesenchymal cells that resemble FIBROBLASTS or muscle cells. The homogeneous mass typically extends into the renal parenchyma and replaces most of the kidney. In most cases, mesoblastic nephroma is benign and occurs in the fetus or newborn, and rarely in the older child or the adult.

A member of the family of TISSUE INHIBITOR OF METALLOPROTEINASES. It is a 21-kDa nonglycosylated protein found in tissue fluid and is secreted as a complex with progelatinase A by human fibroblast and uncomplexed from alveolar macrophages. An overexpression of TIMP-2 has been shown to inhibit invasive and metastatic activity of tumor cells and decrease tumor growth in vivo.

A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.

Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN.

More From BioPortfolio on "A Monotherapy in Subjects With Advanced Solid Tumors"

Quick Search

Searches Linking to this Trial